Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 11;135(24):2192-2195.
doi: 10.1182/blood.2019003722.

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations

Fabienne Lucas  1   2 , Karylin Larkin  1   2 , C Thomas Gregory  1   2 , Shelley Orwick  1   2 , Tzyy-Jye Doong  1   2 , Arletta Lozanski  1   2 , Gerard Lozanski  3 , Shrilekha Misra  1   2 , Apollinaire Ngankeu  1   2 , Hatice Gulcin Ozer  4 , Deepa Sampath  1   2 , Shanmugapriya Thangavadivel  1   2 , Selen A Yilmaz  4 , Kerry A Rogers  1   2 , John C Byrd  1   2   5   6 , Jennifer A Woyach  1   2   5 , James S Blachly  1   2   4
Affiliations

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations

Fabienne Lucas et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.A.W. receives research funding from AbbVie, Janssen, Loxo, Karyopharm, and Morphosys, and has performed consulting for Janssen and Pharmacyclics. J.S.B. has received consulting fees from AbbVie, AstraZeneca, and KITE Pharma. K.A.R. receives research funding from Genentech, AbbVie, and Janssen and has consulted for Acerta Pharma. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Bubble plots of prevenetoclax and postvenetoclax CCFs of mutations in BTK, PLCG2, and BCL2. Bubble size represents cancer cell fraction (CCF; 0% to 100%), and relapse bubble color encodes absolute gain or loss of clone size. Three patients with Richter-type progression are highlighted in red. CCF was adjusted for patient X-chromosome ploidy. Abs. Δ CCF, absolute change in cancer cell fraction.
See this image and copyright information in PMC

References

    1. Jones JA, Mato AR, Wierda WG, et al. . Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65-75. - PMC - PubMed
    1. Seymour JF, Kipps TJ, Eichhorst B, et al. . Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120. - PubMed
    1. Blombery P, Anderson MA, Gong JN, et al. . Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342-353. - PubMed
    1. Tausch E, Close W, Dolnik A, et al. . Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434-e437. - PMC - PubMed
    1. Karczewski KJ, Francioli LC, Tiao G, et al. . Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes [published online ahead of print 13 August 2019]. bioRxiv. doi:10.1101/531210.

Publication types

MeSH terms